美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

F/m Emerald Life Sciences Innovation ETF

47.80

+0.35490.75%

成交量：3,080

成交额：14.77万

市值：1.32亿

市盈率：- -

高：48.06

开：47.84

低：47.78

收：47.44

52周最高：48.78

52周最低：27.34

股本：275.70万

流通股本：275.70万

量比：0.73

换手率：0.11%

股息：- -

股息率：- -

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

第3次更新-足球——谢菲尔德联队前所有者获准申请清算当初收购该俱乐部的那家公司

中国银河证券：实验动物为创新药研发刚需小鼠+猴双主线高景气

美银证券：中国CXO行业受惠生物科技融资强劲上调药明康德等目标价

百花医药股价严重异常波动：主营小分子化学仿制药CRO业务不涉及创新药研发

百花医药(600721.SH)：不涉及创新药研发

百花医药(600721.SH)：不涉及创新药研发

东方证券：AI重构创新药研发底座国内相关产业链公司亦有望受益

Cogent Biosciences拟通过Guggenheim Securities发行高达4亿美元普通股——SEC文件披露

Cogent Biosciences第二季度净亏损9640.5万美元

Spyre Therapeutics推出Spy772项目，启动化脓性汗腺炎SkyLight二期临床试验

LivaNova：预计交易将逐步提升氧合器产能，增强满足客户未满足需求的能力

美国食品药品监督管理局（FDA）批准了Freenome公司用于结直肠癌筛查的血液检测

创新药研发加速遇“猴荒”

市场普遍预计研发管线将迎生死大考诺华制药(NVS)盘前小幅下挫0.18%

英硅智能早盘涨超7% 与康哲药业达成AI+创新药研发新合作

（活力中国调研行）上海生物医药产业规模破万亿张江药谷青年人才成创新药研发主力

中国新闻网

美国食品药品监督管理局批准Vera公司的一款肾病药物

翰思艾泰-B(03378)：拟与华科前沿交叉研究中心打造新一代AI驱动的创新药研发范式

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/stock/LFSC/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LFSC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","market":"US","secType":"STK","nameCN":"F/m Emerald Life Sciences Innovation ETF","latestPrice":47.7953,"timestamp":1787342400000,"preClose":47.4404,"halted":0,"volume":3080,"delay":0,"changeRate":0.00748096559050937,"floatShares":2757035,"shares":2757035,"eps":0,"marketStatus":"盘前交易","change":0.3549,"latestTime":"08-24 05:30:38 EDT","open":47.84,"high":48.06,"low":47.78,"amount":147728.966,"amplitude":0.005902,"askPrice":75.99,"askSize":100,"bidPrice":46.26,"bidSize":11,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787578200000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":47.7953,"sharesOutstanding":2657035,"nav":47.42,"aum":130738599.7,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":47.9,"preClose":47.7953,"latestTime":"19:30 EDT","volume":7,"amount":334.5671,"timestamp":1787355006986,"change":0.1047,"changeRate":0.002191,"amplitude":0},"volumeRatio":0.7335079553807967},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","floatShares":2757035,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.7335079553807967,"shares":2757035,"dividePrice":0,"high":48.06,"amplitude":0.005902,"preClose":47.4404,"low":47.78,"week52Low":27.3402,"pbRate":"--","week52High":48.78,"institutionHeld":0,"latestPrice":47.7953,"committee":-0.801802,"eps":0,"divideRate":0,"volume":3080,"delay":0,"ttmEps":0,"open":47.84,"prevYearClose":36.6147,"prevWeekClose":47.7953,"prevMonthClose":45.55,"prevQuarterClose":45.2033,"fiveDayClose":47.0833,"twentyDayClose":45.1004,"sixtyDayClose":39.0706},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LFSC\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LFSC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LFSC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LFSC\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660421558","title":"第3次更新-足球——谢菲尔德联队前所有者获准申请清算当初收购该俱乐部的那家公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2660421558","media":"路透中文","labels":["policyRegulatory","merge","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660421558?lang=zh_cn&edition=fundamental","pubTime":"2026-08-19 22:49","pubTimestamp":1787150961,"startTime":"0","endTime":"0","summary":"第3次更新-足球——谢菲尔德联队前所有者获准申请清算当初收购该俱乐部的那家公司在第4至5段中补充了谢菲尔德联队的声明路透伦敦8月19日-谢菲尔德联队前所有者周三获准申请，将清算该公司——该公司在2024年收购了这支英冠球队。谢菲尔德联队表示，高等法院的裁决对俱乐部而言并非问题。但今年6月，谢菲尔德联队表示1919 Partners LLC是该俱乐部的母公司，对此，United World本周表示，此举“似乎是试图逃避向CSBL的债权人付款”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nL4S44G1AH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory,merge,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH","LFSC","BK4588","EKG","FFOX","LU0320765992.SGD","GNOM","BK4585","HELX","BK4551","BK4535","GDOC","PTH","BK4196","LU0109394709.USD","LU0889565916.HKD","GNMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659504119","title":"中国银河证券：实验动物为创新药研发刚需 小鼠+猴双主线高景气","url":"https://stock-news.laohu8.com/highlight/detail?id=2659504119","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659504119?lang=zh_cn&edition=fundamental","pubTime":"2026-08-14 15:07","pubTimestamp":1786691225,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国银河证券发布研报称，实验动物为创新药研发刚需，行业壁垒深厚，两大细分赛道具备中长期成长逻辑：人源化小鼠赛道成长确定性更强、周期波动平缓;实验猴赛道供给约束强，短期价格上行带来显著业绩弹性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GDOC","BK1147","PBE","IBB","BIOY","161027","BBP","APXH","SBIO","BK0188","BK0276","BK4585","XLVI","WRND","GSKH","601881","BK1564","LFSC","06881","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659138517","title":"美银证券：中国CXO行业受惠生物科技融资强劲 上调药明康德等目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=2659138517","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659138517?lang=zh_cn&edition=fundamental","pubTime":"2026-08-13 12:41","pubTimestamp":1786596060,"startTime":"0","endTime":"0","summary":"模拟交易客户端美银证券发布研报称，受惠上半年全球及中国生物科技一级市场融资表现强劲，加上创新药对外授权交易持续活跃，预期研发活动将进一步加快，中国CRO/CDMO企业可望受惠。该行上调药明康德H股目标价由204.3港元至242港元，药明康德A股目标价由177.8元人民币至210.5元人民币，维持“买入”评级，因其增长能见度清晰。该行并上调药明康德2029至2035年收入估算介乎3%至7%，经调整纯利预测亦上调介乎3%至7%。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2026-08-13/doc-inincxku3329313.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IDNA","WX","SURI","02359","APXH","PSIL","CXO","XBIX","BBC","SMCO","161027","603259","LFSC","FHLC","MEDI","IBRN","PSCH","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658903675","title":"百花医药股价严重异常波动：主营小分子化学仿制药CRO业务 不涉及创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2658903675","media":"央广财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658903675?lang=zh_cn&edition=fundamental","pubTime":"2026-08-12 21:27","pubTimestamp":1786541220,"startTime":"0","endTime":"0","summary":"8月12日，百花医药（维权）（600721.SH）发布公告称，公司股票连续10个交易日内日收盘价格涨幅偏离值累计超过100%，根据上交所的有关规定，属于股票交易严重异常波动情形。公司是以小分子化学仿制药研发为主的CRO企业，不涉及创新药研发。公司2026年第一季度实现营业收入6718.29万元，同比下降30.68%，归属于上市公司股东的净利润664.27万元，同比下降67.94%。目前公司主营业务未发生重大变化，市场环境、行业政策没有发生重大调整，股价短期内连续上涨，涨幅与公司经营情况严重偏离。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-12/doc-ininamih5206238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["APXH","BIOY","BK0102","BK4588","GSKH","LFSC","GDOC","SBIO","BK4585","IBB","WRND","600721","PBE","BK0216","BBP","XLVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658692990","title":"百花医药(600721.SH)：不涉及创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2658692990","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658692990?lang=zh_cn&edition=fundamental","pubTime":"2026-08-11 20:03","pubTimestamp":1786449780,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","BIOY","GSKH","GDOC","WRND","PBE","XLVI","BBP","IBB","APXH","BK4588","LFSC","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658667990","title":"百花医药(600721.SH)：不涉及创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2658667990","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658667990?lang=zh_cn&edition=fundamental","pubTime":"2026-08-11 20:03","pubTimestamp":1786449780,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百花医药(600721.SH)发布股票交易风险提示公告称，公司是以小分子化学仿制药研发为主的CRO企业，主营业务是为客户提供小分子化仿药为主的药物研发注册“一站式”全流程服务，主要研发项目多来自于客户委托加部分的公司自主立项，不涉及创新药研发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478640.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBB","LFSC","600721","BIOY","BK0102","GSKH","BBP","PBE","WRND","APXH","BK0216","BK4585","BK4588","GDOC","SBIO","XLVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658962968","title":"东方证券：AI重构创新药研发底座 国内相关产业链公司亦有望受益","url":"https://stock-news.laohu8.com/highlight/detail?id=2658962968","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658962968?lang=zh_cn&edition=fundamental","pubTime":"2026-08-11 14:06","pubTimestamp":1786428403,"startTime":"0","endTime":"0","summary":"东方证券主要观点如下：技术颠覆成本，AI重构制药“快与省”是中国创新药崛起的底层逻辑，根基是人才红利和成本优势。专家与AI协同，将真正提升新药研发的成功率并缩短周期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478422.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBB","BK0188","BIOY","WRND","BK4585","CHAT","BK1564","BK0276","AGIX","LFSC","PBE","GSKH","BK0183","BBP","APXH","BK1147","03958","ARTY","AIPO","QTOC","BK0028","VTHR","BK0012","BK4588","SBIO","GDOC","XLVI","600958"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189948002","title":"Cogent Biosciences拟通过Guggenheim Securities发行高达4亿美元普通股——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1189948002","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189948002?lang=zh_cn&edition=fundamental","pubTime":"2026-08-11 05:19","pubTimestamp":1786396748,"startTime":"0","endTime":"0","summary":"Cogent Biosciences公司——根据其向美国证券交易委员会提交的文件显示，该公司可能通过Guggenheim Securities进行高达4亿美元的普通股公开发售。这一动向，无疑为市场注入了新的关注点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","LFSC","CANC","COGT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173801167","title":"Cogent Biosciences第二季度净亏损9640.5万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1173801167","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173801167?lang=zh_cn&edition=fundamental","pubTime":"2026-08-10 20:15","pubTimestamp":1786364138,"startTime":"0","endTime":"0","summary":"Cogent Biosciences（股票代码：COGT）发布了第二季度财报。数据显示，公司在运营方面出现了1.02638亿美元的亏损，由此导致净亏损达9640.5万美元。这一财务表现反映出公司当期面临的挑战。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COGT","LFSC","BK4139","CANC","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150250995","title":"Spyre Therapeutics推出Spy772项目，启动化脓性汗腺炎SkyLight二期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1150250995","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150250995?lang=zh_cn&edition=fundamental","pubTime":"2026-08-10 20:01","pubTimestamp":1786363318,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics（股票代码：SYRE）正式宣布，其全新研发项目Spy772已启动，并同步开启针对化脓性汗腺炎（Hidradenitis Suppurativa）的SkyLight二期临床试验。这一消息标志着公司在炎症性疾病治疗领域迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LFSC","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178169770","title":"LivaNova：预计交易将逐步提升氧合器产能，增强满足客户未满足需求的能力","url":"https://stock-news.laohu8.com/highlight/detail?id=1178169770","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178169770?lang=zh_cn&edition=fundamental","pubTime":"2026-08-05 18:15","pubTimestamp":1785924909,"startTime":"0","endTime":"0","summary":"LivaNova宣布，一项交易预计将有助于逐步提升其氧合器的产量。随着时间的推移，这一举措将显著增强公司满足客户潜在且尚未被满足的订单需求的能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2125909593.SGD","IE00BQXX3C00.GBP","LU1854104046.USD","LU1291159041.SGD","LU0345770993.USD","HRTS","BK4585","LU1923622291.USD","LU2089984988.USD","LU2357305700.SGD","LU1983299246.USD","LU0061474960.USD","LU0342679015.USD","LU1061106388.HKD","LU2264538146.SGD","LU0316494557.USD","LU2764262908.HKD","LU2125909759.SGD","LU2065171311.SGD","LU1670627923.USD","IE00BQXX3F31.USD","LU0823416689.USD","BK4588","IE00BJJMRZ35.SGD","LU1923622614.USD","IE00BQXX3D17.EUR","LIVN","LU2468319806.SGD","IE0034235188.USD","IE0002141913.USD","LU0528227936.USD","LU1023059063.AUD","LU1720051017.SGD","LU2092937221.SGD","LU2298321311.HKD","IE00BKPKM429.USD","LU2125909916.SGD","LU1670628061.USD","LU2433249047.HKD","LU2543165471.USD","LU1791710582.SGD","LU1988902786.USD","LU1623119135.USD","LU2125910179.SGD","IE00BFTCPJ56.SGD","LU2764263039.SGD","LU0266013472.USD","BK4566","GNMX","LU1989771016.USD","LU2360108059.USD","LU1064131342.USD","LU1153585028.USD","IE00B19Z9505.USD","LU0114720955.EUR","LU1854103824.USD","LU1057294990.SGD","BK4121","IE00B19Z8W00.USD","LU0011850046.USD","BK4533","GB00BDT5M118.USD","LU0957791311.USD","LU1803068623.USD","LU2764263203.CNY","LU0432979614.USD","LU2065171402.SGD","LU2211814178.USD","LFSC","LU0122379950.USD","IE00BJT1NW94.SGD","LU1712237335.SGD","IE00B19Z8X17.USD","LU0345770308.USD","LU0320765489.SGD","LU1633808545.USD","LU1720051108.HKD","LU0557290698.USD","LU1815333072.USD","LU2125910336.SGD","IE00B1BXHZ80.USD","TMED","BK4535","IE00B4R5TH58.HKD","LU1548497426.USD","LU2125909247.SGD","LU0070302665.USD","BK4581","TMO","BK4534","LU2065170008.USD","LU2065169927.USD","LU1923621640.USD","LU2211815571.USD","BK4082","LU0640476718.USD","LU0208291251.USD","LU2063271972.USD","BK4548","LU1791710400.SGD","LU2720916845.USD","LU0234572021.USD","IE0009355771.USD","LU0096362180.USD","LU2041044095.USD","IE00B2B36J28.USD","FMED","LU2112291526.USD","LU1280957306.USD","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654048086","title":"美国食品药品监督管理局（FDA）批准了Freenome公司用于结直肠癌筛查的血液检测","url":"https://stock-news.laohu8.com/highlight/detail?id=2654048086","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654048086?lang=zh_cn&edition=fundamental","pubTime":"2026-07-27 21:13","pubTimestamp":1785157998,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局批准了Freenome公司用于结直肠癌筛查的血液检测路透7月27日-两家公司周一表示，美国食品药品监督管理局已批准Freenome公司针对年龄较大的成年人的FRNM.O血液结直肠癌筛查检测，为合作伙伴雅培公司今秋在美国推出该产品铺平了道路。美国食品药品监督管理局批准该检测适用于45岁及以上中风险成年人，这使Freenome拥有了其首个商业化产品。根据2025年签署的商业化协议，Freenome将从雅培公司获得与此次批准相关的1亿美元里程碑付款。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nL4T43T12N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","SG9999004303.SGD","LU1914381329.SGD","IHI","LU2112291526.USD","BK4566","BK4533","LU0266013472.USD","GH","LU0889565916.HKD","FRNM","IE0002141913.USD","PTH","HELX","FFOX","SG9999002232.USD","BK4568","PJP","GNMX","BK4585","LU0234572021.USD","IE00B2B36J28.USD","LU0882574055.USD","LU2237957902.USD","LU0170899867.USD","IE00BJJMRZ35.SGD","LU2237957811.SGD","GNOM","SG9999002224.SGD","GDOC","BK4082","BK4535","LU0432979614.USD","LU0868494617.USD","LU0320765992.SGD","LU2468319806.SGD","EKG","LU0122379950.USD","LU1721429741.USD","LU0058720904.USD","LU1989763690.USD","BK4588","LU1989763427.SGD","BK4551","ABT","SGXZ23171101.USD","LU2211815571.USD","LU2133065610.SGD","LU1061106388.HKD","TMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653584157","title":"创新药研发加速遇“猴荒”","url":"https://stock-news.laohu8.com/highlight/detail?id=2653584157","media":"三里河","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653584157?lang=zh_cn&edition=fundamental","pubTime":"2026-07-22 16:21","pubTimestamp":1784708497,"startTime":"0","endTime":"0","summary":"“要站在‘猴’里，不要像猴子一样站在那里。”资本市场从来不缺故事。近期，昭衍新药业绩暴增，原因是实验猴市场价格上涨，带动公司手里的“猴子资产”大幅增值，多家相关概念公司股价也跟风大涨。甚至有人顺藤摸瓜，挖出了“香蕉概念”。网友戏称：这是产业链挖掘最深的一次。一只猴子，为什么能扰动资本市场？答案藏在药物的研发链条里。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607223817277458.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607223817277458.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["SBIO","XLVI","BK4585","WRND","LFSC","APXH","IBB","BBP","BIOY","BK4588","GDOC","GSKH","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652962294","title":"市场普遍预计研发管线将迎生死大考 诺华制药(NVS)盘前小幅下挫0.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652962294","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652962294?lang=zh_cn&edition=fundamental","pubTime":"2026-07-20 17:59","pubTimestamp":1784541542,"startTime":"0","endTime":"0","summary":"金吾财讯 | 诺华制药 盘前股价小幅下滑0.18%，最新报153.49美元。消息面上，本周二，瑞士制药巨头诺华制药即将公布最新季度财报。今年下半年，诺华三项决定命运的核心药物临床试验结果将陆续揭晓。3）毫无退路的资本高位：诺华股价今年已累计上涨11%，过去12个月内大涨25%。由于目前全球尚无同类上市药物，这被视为诺华最关键的利润护城河。业绩公布在即，这三款新药的数据能否如期爆发，将直接决定诺华能否渡过这场史上最大的专利危机。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250107/NDZhYjYzMzkxMDg4OTM4.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NDZhYjYzMzkxMDg4OTM4.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302747","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","LFSC","BK4588","IE00B4R5TH58.HKD","MEDX","PPH","IE00BJJMRZ35.SGD","BK4578","BK1191","IE00B2B36J28.USD","LU0320765489.SGD","IE00BJT1NW94.SGD","BK4585","BK4007","LU0208291251.USD","LU0070302665.USD","BK4532","01477","IE0009355771.USD","LU0211331839.USD","IE00BFTCPJ56.SGD","NVS","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651162210","title":"英硅智能早盘涨超7% 与康哲药业达成AI+创新药研发新合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2651162210","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651162210?lang=zh_cn&edition=fundamental","pubTime":"2026-07-13 10:02","pubTimestamp":1783908120,"startTime":"0","endTime":"0","summary":"　　英硅智能早盘涨超7%，截至发稿，股价上涨6.21%，报45.48港元，成交额3.32亿港元。　　7月13日，据英硅智能官微消息，公司宣布与康哲药业在中枢神经系统领域开展另一项AI驱动的药物发现合作。　　根据合作协议，双方将结合英硅智能已验证的AI平台与AI赋能创新药研发能力，以及康哲药业经验丰富的研发团队和对疾病领域的深度认知，双方共同推进该研发项目的合作开发。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-07-13/doc-inihrnpk9058117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2488822045.USD","SG9999015986.USD","VTHR","GDOC","SG9999015952.SGD","SG9999015945.SGD","BK4588","00867","BK1593","CHAT","AGIX","GSKH","WRND","ARTY","IBB","AIPO","SG9999015978.USD","PBE","LFSC","IE00BGHQDM52.EUR","SBIO","BK1191","IE00BVYPNP33.GBP","IE00BYV24P56.USD","QTOC","IE00BVYPNQ40.USD","BBP","SG9999004220.SGD","IE00BMCWC346.EUR","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649952006","title":"（活力中国调研行）上海生物医药产业规模破万亿 张江药谷青年人才成创新药研发主力","url":"https://stock-news.laohu8.com/highlight/detail?id=2649952006","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649952006?lang=zh_cn&edition=fundamental","pubTime":"2026-07-08 11:56","pubTimestamp":1783482969,"startTime":"0","endTime":"0","summary":"中新网上海7月8日电(杨海燕马佳佳)“我们对青年人才‘如饥似渴’，上海团队有180多名全职员工，90%以上都是40岁以下的青年人才。”英硅智能全球对外合作负责人、副总裁王珏7日在“活力中国调研行”主题采访活动中介绍道。在上海张江药谷，这片曾经的农田已崛起为世界级生物医药创新高地，而活跃其中的青年人才，正成为推动创新药研发的主力军。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607083798154946.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607083798154946.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","BBP","399441","GDOC","BK4581","GSKH","IBB","WRND","PBE","BK4585","LFSC","161726","SBIO","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649313139","title":"美国食品药品监督管理局批准Vera公司的一款肾病药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2649313139","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649313139?lang=zh_cn&edition=fundamental","pubTime":"2026-07-08 00:39","pubTimestamp":1783442376,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局批准Vera公司的一款肾病药物路透7月7日-美国食品药品监督管理局周二表示，已批准Vera Therapeutics公司的一款VERA.O药物，用于治疗患有潜在致命性肾脏疾病的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nL4T4391JK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","TVTX","BK4585","VERA","LFSC","BK4539","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649984355","title":"翰思艾泰-B(03378)：拟与华科前沿交叉研究中心打造新一代AI驱动的创新药研发范式","url":"https://stock-news.laohu8.com/highlight/detail?id=2649984355","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649984355?lang=zh_cn&edition=fundamental","pubTime":"2026-07-07 18:57","pubTimestamp":1783421872,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰思艾泰-B 发布公告，为充分发挥产学研结合的优势，加速生物医药研发创新，公司于近日与华科—澳城大高等研究院前沿交叉研究中心正式签署了《“人工智能药物研发联合实验室”合作共建协议》。双方将依托华科前沿交叉研究中心的AI平台，以及翰思艾泰在创新药研发的丰富经验和对疾病领域的深度认知，围绕抗体发现与分子设计展开深度合作，共同打造新一代AI驱动的创新药研发范式。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464249.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CHAT","BK1173","QTOC","SBIO","IBB","AIPO","VTHR","03378","BK4588","GDOC","LFSC","ARTY","AGIX","BK4585","PBE","BK1535","WRND","GSKH","BK1161","BBP"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}]}}